Fatigue assessment in Egyptian patients with hepatitis C virus-related chronic liver disease: Single center study

Table 1 Socio-demographic and clinical data of the participants (n = 300), n (%)/mean ± SD/median (interquartile range)

Variables
Age (years)	57.3 ± 10.6, 59.0 (15.0)
< 45 years	66 (22.0)
45-59 years	110 (36.7)
≥ 60 years	124 (41.3)
Gender
Male	190 (63.3)
Female	110 (36.7)
Marital status
Single	6 (2.0)
Married	258 (86.0)
Divorced	30 (10.0)
Widow	6 (2.0)
Level of education
Illiterate and primary education	96 (32.0)
Secondary education	116 (38.7)
Higher education	88 (29.3)
Residence
Rural	168 (56.0)
Urban	132 (44.0)
Smoking
No	216 (72.0)
Yes	58 (19.3)
Ex smoker	26 (8.7)
Co-morbidities (yes)1	150 (50.0)
Clinical stage
Chronic liver disease	52 (17.3)
Compensated	174 (58.0)
Decompensated	72 (24.0)
Child score (n = 248)
A	170 (68.5)
B	28 (11.3)
C	50 (20.2)
Ascites (yes)	79 (26.3)
History of GIT bleeding (yes)	56 (18.7)
History of hepatic encephalopathy (yes)	51 (17)
HCV infection duration
< 10 years	159 (53.0)
≥ 10 years	141 (47.0)
Antiviral treatment (yes)	262 (87.3)
The duration of last dose of antiviral treatment (n = 262)
< 1 year	6 (2.0)
≥ 1 year	256 (97.7)
Antiviral treatment response (n = 262)
Response	247 (94.3)
Failure	15 (5.7)
MELD score	9.2 (3.1)
ALT	29.0 (19.3)
AST	32.0 (24.8)
Total bilirubin (mg/dL)	1.0 (0.6)
Albumin (g/dL)	3.8 (0.7)
Creatinine (mg/dL)	0.90 (0.3)
INR	1.1 (0.1)
Platelet	155.0 (140.0)

¹Comorbidities (including diabetes mellitus and hypertension), hepatitis C virus.

MELD: Model for end-stage liver disease; GIT bleeding: Gastrointestinal tract bleeding; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio; HCV: Hepatitis C virus.